

REXAHN PHARMACEUTICALS, INC.

Form 8-K

November 05, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): November 5, 2015

Rexahn Pharmaceuticals, Inc.  
(Exact Name of Registrant as Specified in its Charter)

Delaware 001-34079 11-3516358  
(State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

15245 Shady Grove Road, Suite 455 Rockville, MD 20850  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (240) 268-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

Section 8 – Other Events

Item 8.01 Other Events.

On November 5, 2015, Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing interim clinical data from an ongoing Phase IIa study of Archexin®, the Company’s novel inhibitor of the protein kinase phosphorylated Akt-1 in development for the treatment of cancer. The results will be presented on Friday, November 6, 2015 at the 14<sup>th</sup> International Kidney Cancer Symposium in Miami, Florida. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit</u> <u>No.</u>	<u>Description</u>
<u>99.1</u>	Rexahn Pharmaceuticals, Inc. press release dated November 5, 2015, announcing the presentation of interim clinical data.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REXAHN PHARMACEUTICALS, INC.

Date: November 5, 2015 /s/ Tae Heum Jeong

Tae Heum Jeong

Senior Vice President of Finance and Chief Financial Officer

---